AXA Medicine sits in strategic cooperation with the National Blood System Clinical Medical Center

Guide: The two sides will jointly jointly build the "National Blood System Clinical Medical Research Center Of Asia Research Institute"July 3, AXA Medicine and the National Blood System Clinical Medical Research Center held a signing ceremony to jointly build the "National Blood System Clinical Medical Research Center AXain Research Institute" signed a strategic cooperation agreement, plus the field of blood tumor research and clinical developmentSuzhou Municipal Committee Standing Committee, Industrial Park Party Secretary Wu Qingwen, Suzhou University Party Standing Committee, Vice President, Su Da annex I Party Secretary Chen Weichang, Suzhou Health and Health Committee Director Tan Weiliang, National Blood System Disease Clinical Medical Research Center Executive Deputy Director, Chinese Medical Association Blood Credit Committee Member, Suzhou University Affiliated First Hospital Hematology Director Wu Depei, Asheng Medical Chairman, CEO Yang Jun, etcWith the launch of the "Full-scale Construction of Suzhou Biopharmaceutical Industry Landmark Implementation Program (2020-2030)," Suzhou has trumpeted the trumpet of building an internationally renowned, most representative of the country's most representative identity, the most influential competitive trillion-level"China Pharmaceutical Valley", accelerating the capacity-building of local clinical research and building a number of pharmaceutical landmark enterprises is one of the important contentsagainst this background, Asheng Pharmaceuticals, which was named the first batch of Suzhou Potential Landmark Enterprise Seogio, actively explored and reached a comprehensive strategic cooperation with the National Research Center for Blood System Diseases of Suzhou Key Clinical Research InstitutionsThe two sides will jointly jointly build the "National Research Center for Clinical Medicine of Blood System Diseases" to focus on the field of blood tumors, and carry out comprehensive and in-depth cooperation in the areas of basic cancer research, clinical treatment research, innovative drug research and development, innovative talent training, and cultivation of key core technology platformsthe signing site, under the framework of strategic cooperation, the two sides also signed cooperation agreements on the following five projects:BCL-2 New Inhibitor APG-2575 In Mechanism and Clinical Study in Multiple MyelomaClinical Study of BCL-2 New Inhibitor APG-2575 In Fahrenheit Throemisis (WM)BCL-2 New Inhibitor APG-2575 Single Drug and Combined Treatment in Acute Mixed Pymopathic Leukemia (MPAL) Clinical ResearchOriginal New Drug HQPP1351 Target Research into the transformation of FGFR1 or NTRK family kinases in blood tumors
new apoptosis pathway small molecular inhibitor APG-2575 joint agma7in adnessanosis APG-115 in the preclinical evaluation and clinical research of blood tumors
the two sides to give full play and combine their respective comprehensive resource advantages, further enhance the local clinical research capability in Suzhou, accelerate the transformation of original new drugs of landmark enterprises, and help Suzhou "China Pharmaceutical Valley" development, benefit more patients